ESR1 and cancer: The full model showed good discrimination in most subgroups of the test data set (AUROC 0.70-0.87), except in the ER–/PR–/HER2– and hormone receptor (HR)+/HER2+ subgroups for disease progression and cancer-specific mortality (AUROC 0.63-0.69).